Literature DB >> 11836976

Low-dose dexamethasone challenge in women with atypical major depression: pilot study.

Robert D Levitan1, Franco J Vaccarino, Gregory M Brown, Sidney H Kennedy.   

Abstract

OBJECTIVE: To examine if atypical depression may be associated with hypersuppression of the hypothalamic-pituitary-adrenal (HPA) axis.
METHOD: Eight women with atypical major depression and 11 controls with no history of psychiatric illness, matched on age and body mass index, were challenged with low-dose dexamethasone (0.25 mg and 0.50 mg in random order and 1 week apart). Dexamethasone was self administered at 11 pm, and plasma cortisol samples were drawn at 8 am and 3 pm on the following day.
RESULTS: After the 0.50-mg dexamethasone challenge, mean suppression of morning cortisol was significantly greater in patients with atypical depression (91.9%, standard deviation [SD] 6.8%) than in the controls (78.3%, SD 10.7%; p < 0.01).
CONCLUSION: These preliminary data add to the growing body of literature that suggests atypical depression, in contrast to classic melancholia, may be associated with exaggerated negative feedback regulation of the HPA axis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836976      PMCID: PMC149795     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  14 in total

1.  Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series.

Authors:  C Bouwer; J Claassen; T G Dinan; C B Nemeroff
Journal:  Depress Anxiety       Date:  2000       Impact factor: 6.505

2.  Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features.

Authors:  H Anisman; A V Ravindran; J Griffiths; Z Merali
Journal:  Mol Psychiatry       Date:  1999-03       Impact factor: 15.992

3.  Use of the dexamethasone suppression test in depression.

Authors:  B J Carroll
Journal:  J Clin Psychiatry       Date:  1982-11       Impact factor: 4.384

4.  Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder.

Authors:  R Yehuda; D Boisoneau; M T Lowy; E L Giller
Journal:  Arch Gen Psychiatry       Date:  1995-07

5.  Defining the boundaries of atypical depression.

Authors:  F M Quitkin; W Harrison; M Liebowitz; P McGrath; J G Rabkin; J Stewart; J Markowitz
Journal:  J Clin Psychiatry       Date:  1984-07       Impact factor: 4.384

6.  Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo.

Authors:  F M Quitkin; J W Stewart; P J McGrath; E Tricamo; J G Rabkin; K Ocepek-Welikson; E Nunes; W Harrison; D F Klein
Journal:  Br J Psychiatry Suppl       Date:  1993-09

7.  Atypical depression.

Authors:  J R Davidson; R D Miller; C D Turnbull; J L Sullivan
Journal:  Arch Gen Psychiatry       Date:  1982-05

8.  Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications.

Authors:  J R Joseph-Vanderpool; N E Rosenthal; G P Chrousos; T A Wehr; R Skwerer; S Kasper; P W Gold
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

Review 9.  Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs.

Authors:  P W Gold; J Licinio; M L Wong; G P Chrousos
Journal:  Ann N Y Acad Sci       Date:  1995-12-29       Impact factor: 5.691

Review 10.  Clinical significance of psychoneuroendocrinology in psychiatry: focus on the thyroid and adrenal.

Authors:  C B Nemeroff
Journal:  J Clin Psychiatry       Date:  1989-05       Impact factor: 4.384

View more
  12 in total

1.  Lack of elevations in glucocorticoids correlates with dysphoria-like behavior after repeated social defeat.

Authors:  Nicole Bowens; Willem Heydendael; Seema Bhatnagar; Lauren Jacobson
Journal:  Physiol Behav       Date:  2011-11-12

Review 2.  Stress risk factors and stress-related pathology: neuroplasticity, epigenetics and endophenotypes.

Authors:  Jason J Radley; Mohamed Kabbaj; Lauren Jacobson; Willem Heydendael; Rachel Yehuda; James P Herman
Journal:  Stress       Date:  2011-09       Impact factor: 3.493

3.  Atypical depression.

Authors:  Tanvir Singh; Kristi Williams
Journal:  Psychiatry (Edgmont)       Date:  2006-04

4.  Atypical depression is more common than melancholic in fibromyalgia: an observational cohort study.

Authors:  Rebecca L Ross; Kim D Jones; Rachel L Ward; Lisa J Wood; Robert M Bennett
Journal:  BMC Musculoskelet Disord       Date:  2010-06-14       Impact factor: 2.362

5.  Glucocorticoid status affects antidepressant regulation of locus coeruleus tyrosine hydroxylase and dorsal raphé tryptophan hydroxylase gene expression.

Authors:  Willem Heydendael; Lauren Jacobson
Journal:  Brain Res       Date:  2009-07-03       Impact factor: 3.252

6.  Atypical depression in children and adolescents.

Authors:  Wynn Wynn Paing; Ronald A Weller; Lauretta Brennan; Elizabeth B Weller
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

7.  Effect of childhood emotional abuse and age on cortisol responsivity in adulthood.

Authors:  Linda L Carpenter; Audrey R Tyrka; Nicole S Ross; Lamya Khoury; George M Anderson; Lawrence H Price
Journal:  Biol Psychiatry       Date:  2009-04-17       Impact factor: 13.382

Review 8.  Suggested Biomarkers for Major Depressive Disorder.

Authors:  Yunus Hacimusalar; Ertuğrul Eşel
Journal:  Noro Psikiyatr Ars       Date:  2018-05-28       Impact factor: 1.339

Review 9.  Interoception and stress.

Authors:  André Schulz; Claus Vögele
Journal:  Front Psychol       Date:  2015-07-20

Review 10.  Perinatal maternal depression and cortisol function in pregnancy and the postpartum period: a systematic literature review.

Authors:  Sunaina Seth; Andrew J Lewis; Megan Galbally
Journal:  BMC Pregnancy Childbirth       Date:  2016-05-31       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.